Fluorothiazinone has already helped save hundreds of patients, including those with severe postoperative infections, Alexander Gintsburg says
Russia has a drug capable of tackling antibiotic-resistant strains of a bacterium that can cause potentially fatal pneumonia and bloodstream infections and is spreading through European hospitals, a top Russian scientist has said.
Speaking to RIA Novosti on Saturday, Alexander Gintsburg, the scientific director of Russia’s Gamaleya Research Center, weighed in on warnings from the European Center for Disease Prevention and Control (ECDC) over the alarming spread of the Klebsiella pneumoniae bacterium. The watchdog reported on Wednesday that bloodstream infections caused by strains resistant to powerful antibiotics known as carbapenems have increased by 72% in the EU since 2019.
The World Health Organization (WHO) echoed this, saying it found resistance to key antibiotics in at least half of the samples of Klebsiella pneumoniae in around one in two countries in Europe.
Read more US hospitals and nursing homes are breeding grounds for deadly superbugs – CDC
The bacterium normally lives harmlessly in the human gut but can cause pneumonia, urinary tract infections, and potentially deadly bloodstream infections, particularly among hospitalized patients. Some strains even resist last-resort antibiotics, although the EU has several approved drugs that can treat certain resistant infections.
Gintsburg stated that Russia has already rolled out a drug – Fluorothiazinone – that can overcome the threat, noting that it has already helped save hundreds of patients and is being used to treat severe postoperative complications approaching sepsis. He added that the Russian Health Ministry is reviewing documents seeking approval for broader use for antibiotic-resistant infections.
Read more Scientists create viruses with AI
Russia first registered Fluorothiazinone in April 2024 for complex urinary tract infections in combination with cefepime. Unlike conventional antibiotics, it aims to disarm bacteria rather than killing them directly, disrupting mechanisms that help them cause disease.
The drug has undergone several clinical trials. A 2024 randomized trial involving 357 patients found that Fluorothiazinone combined with cefepime achieved a 75.6% cure rate, compared with 50.8% for cefepime and placebo. Researchers also reported no serious adverse events during the study.
Another trial involving 280 patients published in October found effectiveness comparable to a conventional antibiotic against recurrent bladder infections.
The Gamaleya Research Center developed Sputnik V, which was registered in August 2020 as the world’s first Covid-19 vaccine, months ahead of its Western competitors. Gintsburg reportedly tested it on himself and members of his family.
Although the early rollout raised concerns because large-scale trials had not yet been completed, subsequent research published in The Lancet found the vaccine to be 91.6% effective against symptomatic Covid-19.
Despite these results and the nationwide rollout in Russia, Sputnik V never received EU-wide or US authorization amid geopolitical tensions. The EU stalled the process, citing incomplete clinical and manufacturing data, and the vaccine was never submitted to the US Food and Drug Administration. Nevertheless, Hungary and Slovakia broke ranks with the rest of the EU and procured Sputnik V independently during the height of the pandemic.